This page shows the latest U300 news and features for those working in and with pharma, biotech and healthcare.
Meanwhile, a BioChaperone version of the U200 formulation is also in the pipeline, along with an even higher (U300) dose, according to Adocia and Lilly.
Meanwhile, Sanofi has not been resting on its laurels and has already filed for approval of a Lantus follow-up called Toujeo (formerly U300) which promises an improved pharmacodynamic profile with
The regulator will now spend the next few months assessing the safety and efficacy of Toujeo, formerly known as U300, which is a concentrated version of Lantus that has demonstrated an
formerly U300) is able to reduce rates of hypoglycaemia compared to Lantus as well as having less weight gain.
The French company is hoping to be able to bring its Lantus follow-up U300 - which promises to have less potential to cause hypoglycaemia than its parent product - before it loses
Sanofi is firmly focused on bringing a safer version of Lantus called U300 to market before it loses market exclusivity for its top-seller, and R&D chief Elias Zerhouni said
More from news
Approximately 3 fully matching, plus 8 partially matching documents found.
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...